APRE
NASDAQAprea Therapeutics Inc.
News · 26 weeks51-93%
2025-12-142026-06-07
Mix3290d
- SEC Filings16(50%)
- Other8(25%)
- Insider4(13%)
- Leadership3(9%)
- Offering1(3%)
Latest news
25 items- PRAprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid TumorsPresentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across cohortsPatient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027 DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster "Early results
- SECSEC Form SCHEDULE 13G filed by Aprea Therapeutics Inc.SCHEDULE 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)
- SECSEC Form 424B7 filed by Aprea Therapeutics Inc.424B7 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form 10-Q filed by Aprea Therapeutics Inc.10-Q - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateOversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051Additional clinical data from ACESOT-1051 to be provided at the ASCO 2026 Annual Meeting on May 30, 2026$46.5 million in cash and cash equivalents as of March 31, 2026, with anticipated cash runway into Q1 2028 DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of
- SECSEC Form DEFA14A filed by Aprea Therapeutics Inc.DEFA14A - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form DEF 14A filed by Aprea Therapeutics Inc.DEF 14A - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form EFFECT filed by Aprea Therapeutics Inc.EFFECT - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form 424B3 filed by Aprea Therapeutics Inc.424B3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRCatalYm Appoints Christian S. Schade as Chairman of the Board of DirectorsCatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, following the initiation of four late-stage clinical studies of its lead candidate, the GDF-15 inhibitor visugromab. "With recent positive clinical data, multiple ongoing clinical studies, and a strong leadership team with deep biotechnology and drug development expertise, CatalYm is well positioned for continued clinical and corporate success," said Christian S. Schade, Chairman of the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)
- SECSEC Form S-3 filed by Aprea Therapeutics Inc.S-3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual MeetingDOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract "Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)" at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago, IL. Presentation Details:Title:Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in
- SECSEC Form PRE 14A filed by Aprea Therapeutics Inc.PRE 14A - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRFrazier Life Sciences Appoints Christian Schade as Senior AdvisorFrazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Christian Schade as Senior Advisor. Chris will join FLS' Boston office and work closely with the firm's portfolio companies on corporate strategy and business development. "Chris brings deep operational and financial experience with both private and public biopharma companies," said Joe Cabral, Partner at Frazier Life Sciences. "His leadership experience and ability to guide companies through critical inflection points make him a strong addition to our advisory team. We're pleased to welcome him as we continue building out our Boston team." Mr. Schade joins
- INSIDERSEC Form 4 filed by Hamill John P.4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERSEC Form 4 filed by Peters Richard4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementDOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing. Total gross proceeds from the offering are approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the "Offering"). The Offering closed on March 31, 2026. The Company intends to use the upfront net proceeds for general corporate purposes and for research a
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Announces Oversubscribed $30 Million Private PlacementFinancing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other pr
- PRAprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 TrialConfirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitorEmerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic indexA further update from the trial is expected in the second quarter of 2026 DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for
- SECSEC Form EFFECT filed by Aprea Therapeutics Inc.EFFECT - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form 424B3 filed by Aprea Therapeutics Inc.424B3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
APRE FAQ
7 questionsWhat does Aprea Therapeutics Inc. do?
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53...Where does APRE stock trade?
Aprea Therapeutics Inc. (APRE) is listed on NASDAQ.What sector and industry is APRE in?
Aprea Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aprea Therapeutics Inc. go public?
Aprea Therapeutics Inc. (APRE) completed its IPO in 2019.What are analysts saying about APRE?
Aprea Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from JP Morgan: Underweight on 2021-08-20. Recent price targets range from $300.00 to $500.00.What companies are similar to APRE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare APRE side-by-side with any of them on Quantisnow.How can I track APRE on Quantisnow?
Quantisnow aggregates Aprea Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APRE to receive live email and push alerts on every new disclosure.